HR001124C0315 DARPA JUSTIFICATION AND APPROVAL FOR OTHER THAN FULL AND OPEN COMPETITION
Awarded on September 24, 2026. Full description on SAM.gov.
Description
The Ice Control for cold Environments (ICE) program BAA was solicited on August 15, 2022, for the purpose of seeking to develop solutions for extreme cold weather DoW operational challenges by discovering and optimizing biologically sourced or inspired molecules to enable tuned inhibition or nucleation of ice crystallization, propagation, and adhesion. The ICE BAA was solicited for Phase I and Phase II with a notional Phase III that was to be solicited at a later date.
This justification provides the rationale for awarding a sole-source modification to the current Phase II contractor, to continue this work into Phase III under the authority of FAR 6.302-1, "Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements."
Overview
Award Overview
Award Number
HR001124C0315
Award Amount (SAM.gov award notice)
Not specified
Award Date
Sep 24, 2026
Awardee
Not specified
Original Solicitation
Notice ID: 0ec0d027c57c45bb9d97d4e6410d2c82
Posted Date: Oct 16, 2026
Original Response Deadline: Not specified
Possible prior contracts
Sign in to see possible prior contracts for this requirement (matched by agency, NAICS and place of performance; not confirmed).
Contacts
Contracting Officer
Primary Contact
Documents
Files (1)
- Download
Justification_and_Approval_-_ICE_Program Fully U. of Michigan_Redacted.pdf
316 KBAdded in Justification version 4Posted
Lifecycle
- 3Version 3Award NoticeArchived
HR001124C0315 Ice Control for cold Environments (ICE)
- 4Version 4JustificationCurrent
Type changed from Award Notice to Justification
HR001124C0315 DARPA JUSTIFICATION AND APPROVAL FOR OTHER THAN FULL AND OPEN COMPETITION
Similar Opportunities
Title | Phase | Agency | NAICS | Set Aside | Posted | Deadline | Location |
|---|---|---|---|---|---|---|---|
The Biological Technologies Office (BTO) of the Defense Advanced Research Projects Agency (DARPA) will host a Second Industry Day for potential competitors in the DARPA Surgical Competition (DSC). The Second Industry Day will be held on Wednesday November 4th, 2026, from 4:00 PM to 6:00 PM virtually. Advance registration is required. Note: all times listed in this announcement and on the registration website are Eastern Time. | Special Notice | 541714 | No Set-Aside | 10/14/2026 | 11/02/2026 | - | |
The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) is soliciting proposals that leverage biological properties and processes to revolutionize our ability to protect the nation’s warfighters. Specifically excluded is research that primarily results in evolutionary improvements to the existing state of practice. | Solicitation | 541714 | No Set-Aside | 10/01/2025 | 09/30/2026 | - | |
THIS NOTICE IS NOT A REQUEST FOR PROPOSALS OR A COMPETITIVE SOLICITATION. The Defense Advanced Research Projects Agency (DARPA) intends to enter into an Agreement with The University of Texas System consortium of universities in support of the Biological Technologies Office (BTO) LiveChain Program for an integrated research initiative focused on autonomous medical care, casualty evacuation, clinical decision support, and resilient medical supplies in austere and contested environments. | Special Notice | 541714 | No Set-Aside | 10/16/2026 | 11/15/2026 | - | |
The Ice Control for cold Environments (ICE) program BAA was solicited on August 15, 2022, for the purpose of seeking to develop solutions for extreme cold weather DoW operational challenges by discovering and optimizing biologically sourced or inspired molecules to enable tuned inhibition or nucleation of ice crystallization, propagation, and adhesion. The ICE BAA was solicited for Phase I and Phase II with a notional Phase III that was to be solicited at a later date. This justification provides the rationale for awarding a sole-source modification to the current Phase II contractor, to continue this work into Phase III under the authority of FAR 6.302-1, "Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements." | Sole Source / J&A | 541714 | No Set-Aside | 10/16/2026 | Open | Boston, MA | |
The Congressionally Directed Medical Research Programs (CDMRP) seeks feedback to inform potential future Lupus Research Program (LRP) focus areas and associated research funding opportunities. Although fiscal year 2027 (FY27) funds have not been appropriated, the LRP is requesting this information to support program planning processes. The CDMRP wants to hear from all audiences, interested parties, and individuals from academia, industry, community and non-profit organizations, scientific and professional organizations, federal agencies, and the public. This RFI is for information and planning purposes only and should not be construed as a solicitation or an obligation on the part of the LRP or the Department of War. BACKGROUND: The CDMRP represents a unique partnership between the U.S. Congress, the military, and the public to fund innovative and impactful medical research in targeted program areas. The CDMRP LRP’s vision is to cure lupus through partnership of scientists, clinicians and persons affected by lupus. The LRP’s mission is to fund research to understand, prevent, and diagnose lupus and to improve treatments and quality of life of patients, including Service Members and their Families, Veterans and the general public. Appropriations for the LRP from FY17-24 and FY26 totaled $75 million. As of October 2026, FY27 funds for the LRP have not been appropriated. If appropriated, the CDMRP will utilize its two-tier review process https://cdmrp.health.mil/about/2tierRevProcess) to efficiently manage the LRP. Additional information about the LRP can be found here: https://cdmrp.health.mil/lrp/ RESPONSE INSTRUCTIONS: Please provide responses to this RFI by clicking on the following link: https://www.surveymonkey.com/r/FY27-LRP-RFI | Market Research | 541714 | No Set-Aside | 10/15/2026 | 11/16/2026 | Frederick, MD |
Additional Details
Solicitation Number
HR001124C0315
Archive Date
Nov 15, 2026
Office Address
ARLINGTON, VA, 222032114